SCHEMBL5459909

SCHEMBL5459909

Cc1ccc(C)c(NC(=O)Nc2ccc(N3CCN(C(=O)OC(C)(C)C)CC3)cc2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.56
MAPT P10636 5/20 0.56
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
TSHR P16473 1/20 0.56
GPR119 Q8TDV5 2/20 0.55
CYP2C19 P33261 4/20 0.52
LMNA P02545 3/20 0.50
CYP3A4 P08684 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
CCNK O75909 1/20 0.49
CCNA2 P20248 1/20 0.49
CDK2 P24941 1/20 0.49
CCND3 P30281 1/20 0.49
CDK9 P50750 1/20 0.49
CDK6 Q00534 1/20 0.49
ALDH1A1 P00352 3/20 0.49
CYP1A2 P05177 1/20 0.47
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5465333 0.90 MAPT (0.56) NAMPTMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5467284 0.90 MAPT (0.56) NAMPTMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5465659 0.90 NAMPT (0.54) NAMPTMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5460860 0.90 NAMPT (0.54) NAMPTMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5455872 0.89 MAPT (0.56) NAMPTMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5457972 0.87 NAMPT (0.64) NAMPTMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5456893 0.87 GPR119 (0.54) NAMPTMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5458258 0.86 MAPT (0.53) NAMPTMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5465547 0.86 MAPT (0.53) NAMPTMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5458477 0.85 NAMPT (0.61) NAMPTMAPTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 NAMPT 324/4885MAPT 758/4885MEN1 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.